Reproductive BioMedicine Online
Volume 19, Issue 4 , Pages 478-485 , October 2009

Use of aromatase inhibitors in poor-responder patients receiving GnRH antagonist protocols

  • Batuhan Ozmen

      Affiliations

    • Center for Research on Human Reproduction, School of Medicine, University of Ankara, Ankara, Turkey
    • Department of Obstetrics and Gynecology, School of Medicine, University of Ankara, Ankara, Turkey
    • Corresponding Author InformationCorrespondence:
    • ,
  • Murat Sönmezer

      Affiliations

    • Center for Research on Human Reproduction, School of Medicine, University of Ankara, Ankara, Turkey
    • Department of Obstetrics and Gynecology, School of Medicine, University of Ankara, Ankara, Turkey
    • ,
  • Cem Somer Atabekoglu

      Affiliations

    • Center for Research on Human Reproduction, School of Medicine, University of Ankara, Ankara, Turkey
    • Department of Obstetrics and Gynecology, School of Medicine, University of Ankara, Ankara, Turkey
    • ,
  • Hülya Olmuş

      Affiliations

    • Department of Statistics, Faculty of Science and Art, University of Gazi, Ankara, Turkey

Received 24 October 2008 ,Revised 12 December 2008 ,Accepted 11 May 2009.

References 

  1. Barroso G, Menocal G, Felix H, et al. Comparison of the efficacy of the aromatase inhibitor letrozole and clomiphene citrate as adjuvants to recombinant follicle-stimulating hormone in controlled ovarian hyperstimulation: a prospective, randomized, blinded clinical trial. Fertility and Sterility. 2006;86:1428–1431
  2. Bedaiwy MA, Forman R, Mousa NA, et al. Cost-effectiveness of aromatase inhibitor co-treatment for controlled ovarian stimulation. Human Reproduction. 2006;21:2838–2844
  3. Bedaiwy MA, Shokry M, Mousa N, et al. Letrozole co-treatment in infertile women 40 years old and older receiving controlled ovarian stimulation and intrauterine insemination. Fertility and Sterility. 2008;91:2501–2507
  4. Cortínez A, De Carvalho I, Vantman D, et al. Hormonal profile and endometrial morphology in letrozole-controlled ovarian hyperstimulation in ovulatory infertile patients. Fertility and Sterility. 2005;83:110–115
  5. D’Amato G, Caroppo E, Pasquadibisceglie A, et al. A novel protocol of ovulation induction with delayed gonadotropin-releasing hormone antagonist administration combined with high-dose recombinant follicle-stimulating hormone and clomiphene citrate for poor responders and women over 35 years. Fertility and Sterility. 2004;81:1571
  6. Fasouliotis SJ, Laufer N, Sabbagh-Ehrlich S, et al. Gonadotropin-releasing hormone (GnRH)-antagonist versus GnRH-agonist in ovarian stimulation of poor responders undergoing ovulation induction IVF. Journal of Assisted Reproduction and Genetics. 2003;20:455–459
  7. Fisher SA, Reid RL, Van Vugt DA, et al. A randomized double-blind comparison of the effects of clomiphene citrate and the aromatase inhibitor letrozole on ovulatory function in normal women. Fertility and Sterility. 2002;78:280–285
  8. Goswami SK, Das T, Chattopadhyay R, et al. A randomized single-blind controlled trial of letrozole as a low-cost IVF protocol in women with poor ovarian response: a preliminary report. Human Reproduction. 2004;19:2031–2035
  9. Jee BC, Ku SY, Suh CS, et al. Use of letrozole versus clomiphene citrate combined with gonadotropins in intrauterine insemination cycles: a pilot study. Fertility and Sterility. 2006;85:1774–1777
  10. Kailasam C, Keay SD, Wilson P, et al. Defining poor ovarian response during IVF cycles, in women aged <40 years, and its relationship with treatment outcome. Human Reproduction. 2004;19:1544–1547
  11. Lainas TG, Sfontouris IA, Papanikolaou EG, et al. Flexible GnRH antagonist versus flare-up GnRH agonist protocol in poor responders treated by IVF: a randomized controlled trial. Human Reproduction. 2008;23:1355–1358
  12. Mitwally MF, Caspe RF. Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders. Fertility and Sterility. 2002;77:776–780
  13. Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertility and Sterility. 2001;75:305–309
  14. Mitwally MF, Casper RF. Aromatase inhibition reduces gonadotrophin dose required for controlled ovarian stimulation in women with unexplained infertility. Human Reproduction. 2003;18:1588–1597
  15. Mitwally MF, Biljan MM, Casper RF. Pregnancy outcome after the use of an aromatase inhibitor for ovarian stimulation. American Journal of Obstetrics and Gynecology. 2005;192:381–386
  16. Muasher SJ, Abdallah RT, Hubayter ZR. Optimal stimulation protocols for in-vitro fertilization. Fertility and Sterility. 2006;86:267–273
  17. Oktay K, Hourvitz A, Sahin G, et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. Journal of Clinical Endocrinology and Metabolism. 2006;91:3885–3890
  18. Schoolcraft WB, Surrey ES, Minjarez DA, et al. Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol?. Fertility and Sterility. 2008;89:151–156
  19. Shapiro DB, Mitchell-Leef D. GnRH antagonist in in-vitro fertilization: where we are now. Minerva Ginecologica. 2003;55:373–388
  20. Steer R, Mills CJ, Tan SL, et al. The cumulative embryo score: a predictive embryo scoring technique to select the optimal number of embryos to transfer in an in-vitro fertilization and embryo transfer program. Human Reproduction. 1992;1:117–119
  21. Tulandi T, Martin J, Al-Fadhli R, et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertility and Sterility. 2006;85:1761–1765
  22. Verpoest WMJA, Kolibianakis E, Papanikolaou E, et al. Aromatase inhibitors in ovarian stimulation for IVF/ICSI: a pilot study. Reproductive BioMedicine Online. 2006;13:166–172
  23. Yarali H, Esinler I, Polat M, et al. Antagonist/letrozole protocol in poor ovarian responders for intracytoplasmic sperm injection: a comparative study with the microdose flare-up protocol. Fertility and Sterility. 2009;92:231–235

☆ Dr Batuhan Özmen completed his residency programme in obstetrics and gynaecology at University of Ankara in 2003, obtaining his certification in reproductive medicine and artificial reproductive techniques in 2005. In 2006, he worked in the Department of Obstetrics and Gynecology of the University of Schleswig-Holstein in Lübeck under the supervision of Professor Safaa Al-Hasani on laboratory applications in reproductive medicine. He is interested in cryopreservation and vitrification of human gametes, reproductive surgery and human sperm DNA damage. He is now working in the Department of Reproductive Endocrinology at the University of Ankara, Turkey.Dr Batuhan Özmen

PII: S1472-6483(09)00005-4

doi: 10.1016/j.rbmo.2009.05.007

Reproductive BioMedicine Online
Volume 19, Issue 4 , Pages 478-485 , October 2009

Article Tools

* Image Usage & Resolution